FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011053428> ?p ?o ?g. }

• W2011053428 endingPage "e382" @default.
• W2011053428 startingPage "e375" @default.
• W2011053428 abstract "Purpose Parotid-sparing head-and-neck intensity-modulated radiotherapy (IMRT) can reduce long-term xerostomia. However, patients frequently experience weight loss and tumor shrinkage during treatment. We evaluate the use of kilovoltage (kV) cone beam computed tomography (CBCT) for dose monitoring and examine if the dosimetric impact of such changes on the parotid and critical neural structures warrants replanning during treatment. Methods and materials Ten patients with locally advanced oropharyngeal cancer were treated with contralateral parotid-sparing IMRT concurrently with platinum-based chemotherapy. Mean doses of 65 Gy and 54 Gy were delivered to clinical target volume (CTV)1 and CTV2, respectively, in 30 daily fractions. CBCT was prospectively acquired weekly. Each CBCT was coregistered with the planned isocenter. The spinal cord, brainstem, parotids, larynx, and oral cavity were outlined on each CBCT. Dose distributions were recalculated on the CBCT after correcting the gray scale to provide accurate Hounsfield calibration, using the original IMRT plan configuration. Results Planned contralateral parotid mean doses were not significantly different to those delivered during treatment (p > 0.1). Ipsilateral and contralateral parotids showed a mean reduction in volume of 29.7% and 28.4%, respectively. There was no significant difference between planned and delivered maximum dose to the brainstem (p = 0.6) or spinal cord (p = 0.2), mean dose to larynx (p = 0.5) and oral cavity (p = 0.8). End-of-treatment mean weight loss was 7.5 kg (8.8% of baseline weight). Despite a ≥10% weight loss in 5 patients, there was no significant dosimetric change affecting the contralateral parotid and neural structures. Conclusions Although patient weight loss and parotid volume shrinkage was observed, overall, there was no significant excess dose to the organs at risk. No replanning was felt necessary for this patient cohort, but a larger patient sample will be investigated to further confirm these results. Nevertheless, kilovoltage CBCT is a valuable tool for patient setup verification and monitoring of dosimetric variation during radiotherapy. Parotid-sparing head-and-neck intensity-modulated radiotherapy (IMRT) can reduce long-term xerostomia. However, patients frequently experience weight loss and tumor shrinkage during treatment. We evaluate the use of kilovoltage (kV) cone beam computed tomography (CBCT) for dose monitoring and examine if the dosimetric impact of such changes on the parotid and critical neural structures warrants replanning during treatment. Ten patients with locally advanced oropharyngeal cancer were treated with contralateral parotid-sparing IMRT concurrently with platinum-based chemotherapy. Mean doses of 65 Gy and 54 Gy were delivered to clinical target volume (CTV)1 and CTV2, respectively, in 30 daily fractions. CBCT was prospectively acquired weekly. Each CBCT was coregistered with the planned isocenter. The spinal cord, brainstem, parotids, larynx, and oral cavity were outlined on each CBCT. Dose distributions were recalculated on the CBCT after correcting the gray scale to provide accurate Hounsfield calibration, using the original IMRT plan configuration. Planned contralateral parotid mean doses were not significantly different to those delivered during treatment (p > 0.1). Ipsilateral and contralateral parotids showed a mean reduction in volume of 29.7% and 28.4%, respectively. There was no significant difference between planned and delivered maximum dose to the brainstem (p = 0.6) or spinal cord (p = 0.2), mean dose to larynx (p = 0.5) and oral cavity (p = 0.8). End-of-treatment mean weight loss was 7.5 kg (8.8% of baseline weight). Despite a ≥10% weight loss in 5 patients, there was no significant dosimetric change affecting the contralateral parotid and neural structures. Although patient weight loss and parotid volume shrinkage was observed, overall, there was no significant excess dose to the organs at risk. No replanning was felt necessary for this patient cohort, but a larger patient sample will be investigated to further confirm these results. Nevertheless, kilovoltage CBCT is a valuable tool for patient setup verification and monitoring of dosimetric variation during radiotherapy." @default.
• W2011053428 created "2016-06-24" @default.
• W2011053428 creator A5002825869 @default.
• W2011053428 creator A5007536374 @default.
• W2011053428 creator A5014456777 @default.
• W2011053428 creator A5015402624 @default.
• W2011053428 creator A5038617562 @default.
• W2011053428 creator A5060248096 @default.
• W2011053428 creator A5064914663 @default.
• W2011053428 creator A5083048431 @default.
• W2011053428 creator A5083304219 @default.
• W2011053428 creator A5089157372 @default.
• W2011053428 date "2012-03-01" @default.
• W2011053428 modified "2023-10-03" @default.
• W2011053428 title "Monitoring Dosimetric Impact of Weight Loss With Kilovoltage (KV) Cone Beam CT (CBCT) During Parotid-Sparing IMRT and Concurrent Chemotherapy" @default.
• W2011053428 cites W1969719900 @default.
• W2011053428 cites W1993354542 @default.
• W2011053428 cites W2001374473 @default.
• W2011053428 cites W2005887998 @default.
• W2011053428 cites W2010840352 @default.
• W2011053428 cites W2012363631 @default.
• W2011053428 cites W2022394093 @default.
• W2011053428 cites W2025805545 @default.
• W2011053428 cites W2028889097 @default.
• W2011053428 cites W2036152260 @default.
• W2011053428 cites W2046654883 @default.
• W2011053428 cites W2050624834 @default.
• W2011053428 cites W2087991208 @default.
• W2011053428 cites W2102475325 @default.
• W2011053428 cites W2109915923 @default.
• W2011053428 cites W2119917435 @default.
• W2011053428 cites W2142504798 @default.
• W2011053428 cites W2161828429 @default.
• W2011053428 doi "https://doi.org/10.1016/j.ijrobp.2011.07.004" @default.
• W2011053428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22197229" @default.
• W2011053428 hasPublicationYear "2012" @default.
• W2011053428 type Work @default.
• W2011053428 sameAs 2011053428 @default.
• W2011053428 citedByCount "63" @default.
• W2011053428 countsByYear W20110534282012 @default.
• W2011053428 countsByYear W20110534282013 @default.
• W2011053428 countsByYear W20110534282014 @default.
• W2011053428 countsByYear W20110534282015 @default.
• W2011053428 countsByYear W20110534282016 @default.
• W2011053428 countsByYear W20110534282018 @default.
• W2011053428 countsByYear W20110534282019 @default.
• W2011053428 countsByYear W20110534282020 @default.
• W2011053428 countsByYear W20110534282021 @default.
• W2011053428 countsByYear W20110534282022 @default.
• W2011053428 countsByYear W20110534282023 @default.
• W2011053428 crossrefType "journal-article" @default.
• W2011053428 hasAuthorship W2011053428A5002825869 @default.
• W2011053428 hasAuthorship W2011053428A5007536374 @default.
• W2011053428 hasAuthorship W2011053428A5014456777 @default.
• W2011053428 hasAuthorship W2011053428A5015402624 @default.
• W2011053428 hasAuthorship W2011053428A5038617562 @default.
• W2011053428 hasAuthorship W2011053428A5060248096 @default.
• W2011053428 hasAuthorship W2011053428A5064914663 @default.
• W2011053428 hasAuthorship W2011053428A5083048431 @default.
• W2011053428 hasAuthorship W2011053428A5083304219 @default.
• W2011053428 hasAuthorship W2011053428A5089157372 @default.
• W2011053428 hasConcept C126838900 @default.
• W2011053428 hasConcept C141071460 @default.
• W2011053428 hasConcept C181401712 @default.
• W2011053428 hasConcept C2776530083 @default.
• W2011053428 hasConcept C2779813781 @default.
• W2011053428 hasConcept C2780474809 @default.
• W2011053428 hasConcept C2989005 @default.
• W2011053428 hasConcept C509974204 @default.
• W2011053428 hasConcept C544519230 @default.
• W2011053428 hasConcept C71924100 @default.
• W2011053428 hasConcept C75088862 @default.
• W2011053428 hasConceptScore W2011053428C126838900 @default.
• W2011053428 hasConceptScore W2011053428C141071460 @default.
• W2011053428 hasConceptScore W2011053428C181401712 @default.
• W2011053428 hasConceptScore W2011053428C2776530083 @default.
• W2011053428 hasConceptScore W2011053428C2779813781 @default.
• W2011053428 hasConceptScore W2011053428C2780474809 @default.
• W2011053428 hasConceptScore W2011053428C2989005 @default.
• W2011053428 hasConceptScore W2011053428C509974204 @default.
• W2011053428 hasConceptScore W2011053428C544519230 @default.
• W2011053428 hasConceptScore W2011053428C71924100 @default.
• W2011053428 hasConceptScore W2011053428C75088862 @default.
• W2011053428 hasIssue "3" @default.
• W2011053428 hasLocation W20110534281 @default.
• W2011053428 hasLocation W20110534282 @default.
• W2011053428 hasOpenAccess W2011053428 @default.
• W2011053428 hasPrimaryLocation W20110534281 @default.
• W2011053428 hasRelatedWork W1975319276 @default.
• W2011053428 hasRelatedWork W2015659672 @default.
• W2011053428 hasRelatedWork W2035156078 @default.
• W2011053428 hasRelatedWork W2071501053 @default.
• W2011053428 hasRelatedWork W2146328520 @default.
• W2011053428 hasRelatedWork W2408170775 @default.
• W2011053428 hasRelatedWork W2462717890 @default.
• W2011053428 hasRelatedWork W3021064547 @default.
• W2011053428 hasRelatedWork W3185463017 @default.
• W2011053428 hasRelatedWork W4307092306 @default.

• next